Rebleeding and bleeding in the year following intracranial aneurysm coiling: analysis of a large prospective multicenter cohort of 1140 patients-Analysis of Recanalization after Endovascular Treatment of Intracranial Aneurysm (ARETA) Study.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 05 03 2020
revised: 12 04 2020
accepted: 18 04 2020
pubmed: 18 6 2020
medline: 9 2 2021
entrez: 18 6 2020
Statut: ppublish

Résumé

Endovascular treatment is the first line therapy for the management of ruptured and unruptured intracranial aneurysms, but delayed aneurysm rupture leading to bleeding/rebleeding can occur subsequently. ARETA (Analysis of Recanalization after Endovascular Treatment of intracranial Aneurysm) is a prospective, multicenter study conducted to analyze aneurysm recanalization. We analyzed delayed bleeding and rebleeding in this large cohort. 16 neurointerventional departments prospectively enrolled patients treated for ruptured and unruptured aneurysms between December 2013 and May 2015 (ClinicalTrials.gov: NCT01942512). Participant demographics, aneurysm characteristics and endovascular techniques were recorded. Data were analyzed from participants with ruptured or unruptured aneurysms treated by coiling or balloon-assisted coiling. Rates of bleeding and rebleeding were analyzed and associated factors were studied using univariable and multivariable analyses. The bleeding rate was 0.0% in patients with unruptured aneurysms and 1.0% (95% CI 0.3% to 1.7%) in patients with ruptured aneurysms. In multivariate analysis, two factors were associated with rebleeding occurrence: incomplete aneurysm occlusion after initial treatment (2.0% in incomplete aneurysm occlusion vs 0.2% in complete aneurysm occlusion, OR 10.2, 95% CI 1.2 to 83.3; p=0.03) and dome-to-neck ratio (1.5±0.5 with rebleeding vs 2.2±0.9 without rebleeding, OR 0.2, 95% CI 0.04 to 0.8; p=0.03). Modalities of management of aneurysm rebleeding as well as clinical outcomes are described. Aneurysm coiling affords good protection against bleeding (for unruptured aneurysms) and rebleeding (for ruptured aneurysms) at 1 year with rates of 0.0% and 1.0%, respectively. Aneurysm occlusion and dome-to-neck ratio are the two factors that appear to play a role in the occurrence of rebleeding.

Sections du résumé

BACKGROUND BACKGROUND
Endovascular treatment is the first line therapy for the management of ruptured and unruptured intracranial aneurysms, but delayed aneurysm rupture leading to bleeding/rebleeding can occur subsequently. ARETA (Analysis of Recanalization after Endovascular Treatment of intracranial Aneurysm) is a prospective, multicenter study conducted to analyze aneurysm recanalization. We analyzed delayed bleeding and rebleeding in this large cohort.
METHODS METHODS
16 neurointerventional departments prospectively enrolled patients treated for ruptured and unruptured aneurysms between December 2013 and May 2015 (ClinicalTrials.gov: NCT01942512). Participant demographics, aneurysm characteristics and endovascular techniques were recorded. Data were analyzed from participants with ruptured or unruptured aneurysms treated by coiling or balloon-assisted coiling. Rates of bleeding and rebleeding were analyzed and associated factors were studied using univariable and multivariable analyses.
RESULTS RESULTS
The bleeding rate was 0.0% in patients with unruptured aneurysms and 1.0% (95% CI 0.3% to 1.7%) in patients with ruptured aneurysms. In multivariate analysis, two factors were associated with rebleeding occurrence: incomplete aneurysm occlusion after initial treatment (2.0% in incomplete aneurysm occlusion vs 0.2% in complete aneurysm occlusion, OR 10.2, 95% CI 1.2 to 83.3; p=0.03) and dome-to-neck ratio (1.5±0.5 with rebleeding vs 2.2±0.9 without rebleeding, OR 0.2, 95% CI 0.04 to 0.8; p=0.03). Modalities of management of aneurysm rebleeding as well as clinical outcomes are described.
CONCLUSIONS CONCLUSIONS
Aneurysm coiling affords good protection against bleeding (for unruptured aneurysms) and rebleeding (for ruptured aneurysms) at 1 year with rates of 0.0% and 1.0%, respectively. Aneurysm occlusion and dome-to-neck ratio are the two factors that appear to play a role in the occurrence of rebleeding.

Identifiants

pubmed: 32546636
pii: neurintsurg-2020-015971
doi: 10.1136/neurintsurg-2020-015971
doi:

Banques de données

ClinicalTrials.gov
['NCT01942512']

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1219-1225

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Laurent Pierot (L)

Radiology, CHU Reims, Reims, Champagne-Ardenne, France lpierot@gmail.com.

Coralie Barbe (C)

Department of Research and Public Health, CHU Reims, Reims, Champagne-Ardenne, France.

Denis Herbreteau (D)

Neuroradiology, CHRU Tours, Tours, Centre, France.

Jean-Yves Gauvrit (JY)

Neuroradiology, CHU Rennes, Rennes, Bretagne, France.

Anne-Christine Januel (AC)

Neuroradiology, CHU Toulouse, Toulouse, Midi-Pyrénées, France.

Fouzi Bala (F)

Interventional neuroradiology, CHRU Lille Pôle Spécialités Médicochirurgicales, Lille, Hauts-de-France, France.

Frédéric Ricolfi (F)

Neuroradiology, CHU Dijon, Dijon, Bourgogne, France.

Hubert Desal (H)

Neuroradiology, CHU Nantes, Nantes, Pays de la Loire, France.

Stéphane Velasco (S)

Radiology, CHU Poitiers, Poitiers, France.

Mohamed Aggour (M)

Neuroradiology, CHU Saint-Étienne, Saint-Etienne, Rhône-Alpes, France.

Emmanuel Chabert (E)

Neuroradiologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Jacques Sedat (J)

Neurointerventionnel, CHU Nice, Nice, Provence-Alpes-Côte d'Azu, France.

Denis Trystram (D)

neuroradiology, CH Sainte Anne, Paris, Île-de-France, France.

Gaultier Marnat (G)

Interventional and Diagnostic Neuroradiology, CHU de Bordeaux, Bordeaux, Aquitaine, France.

Sophie Gallas (S)

Neuroradiology, CHU Bicêtre, Le Kremlin-Bicetre, Île-de-France, France.

Georges Rodesch (G)

Neuroradiology, Hopital Foch, Suresnes, Île-de-France, France.

Frédéric Clarençon (F)

Neuroradiology, IFR des Neurosciences CHU Pitie-Salpetriere IFR 70, Paris, Île-de-France, France.

Chrysanthi Papagiannaki (C)

Interventional Neuroradiology, CHU Rouen, Rouen, Normandie, France.

Phil White (P)

Institute for Ageing & Health, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.
Neuroradiology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.

Laurent Spelle (L)

Interventional Neuroradiology, CHU Bicêtre, Le Kremlin-Bicetre, Île-de-France, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH